March 2019 - QuartzBio

March 6, 2019 — Bethesda, MD — Precision for Medicine, part of Precision Medicine Group, today announced the acquisition of SimplicityBio, adding artificial intelligence to Precision’s QuartzBio™ multiomic data integration and informatics platform. The addition of an artificial intelligence engine to QuartzBio provides Precision’s clients the most robust, sophisticated end-to-end solution for the “big data” challenge observed in biomarker-guided drug development—furthering their mission of maximizing the value and utility of biomarker data generated in the course of a clinical trial.

QuartzBio is the only company purpose-built to deliver end-to-end Sample and Biomarker Intelligence for clinical-stage biopharma teams. Powered by a network of domain-specific AI agents, our solutions transform fragmented data into actionable intelligence, enabling conversational insights into your unified ecosystem of sample, clinical, and biomarker data.